ProgenityLogo.jpg
Sean Lavin, MD, Joins Progenity as Vice President, Business Development, Strategy, and Investor Relations
May 25, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Sean Lavin, M.D. as Vice President, Business...
ProgenityLogo.jpg
Progenity Announces Poster Presentations at Digestive Disease Week 2021
May 24, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the presentation of two posters related to the company’s Targeted...
ProgenityLogo.jpg
Progenity Joins Global Call to Raise Awareness of Preeclampsia in Pregnancy on World Preeclampsia Day – May 22nd
May 21, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, May 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
ProgenityLogo.jpg
Progenity Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 13, 2021 16:03 ET | Progenity, Inc.
Reports revenues of $24.5 million in the first quarter of 2021, up 72% from prior quarter Announced pre-validation data for its Preecludia™ test showed strong performance consistent with...
ProgenityLogo.jpg
Progenity Provides Preliminary Results from Key Studies for its Targeted Therapeutics Program
May 12, 2021 07:29 ET | Progenity, Inc.
SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced preliminary results, subject to final audited study reports by its...
ProgenityLogo.jpg
Progenity Receives Funding from Crohn’s & Colitis Foundation IBD Ventures Fund to Develop Drug Delivery System for IBD
May 11, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
ProgenityLogo.jpg
Progenity to Report First Quarter 2021 Financial Results and Provide Corporate Update
May 06, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
ProgenityLogo.jpg
Progenity Provides Key Update Regarding its Preecludia™ Test for Preeclampsia
May 05, 2021 07:30 ET | Progenity, Inc.
SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
ProgenityLogo.jpg
Survey Reveals Pregnant Women Lack Awareness About Preeclampsia, the #2 Cause of Maternal Death
May 04, 2021 07:30 ET | Progenity, Inc.
Progenity survey shows more women know their baby’s “fruit size” than the key indicator of a common pregnancy complication Preeclampsia Awareness Month aims to educate women about the potentially...
ProgenityLogo.jpg
Progenity Presents Key Verification Study Data for Preecludia™ Preeclampsia Rule-out Test at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
April 30, 2021 16:04 ET | Progenity, Inc.
SAN DIEGO, April 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...